13F Holdings
中文EN

EPRX EUPRAXIA PHARMACEUTICALS INC. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1581178 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-51.3%
TTM EPS YoY-35.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.8%
ROA-63.7%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.6%
Debt / equity0.00x
Current ratio15.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$0$0$0—
R&D expense$21.33M$16.08M$20.36M$13.63M
SG&A expense$17.10M$10.92M$7.48M$3.99M
Interest expense$0$603,573$1.17M$982,856
Pretax income-$38.59M-$25.74M-$28.93M-$18.99M
Income tax$19,091$1,804$36,423$0
Net income-$38.58M-$25.50M-$28.22M-$18.49M
EPS (basic)-1.03-0.76-1.17-0.96
EPS (diluted)-1.03-0.76-1.17-0.96
Weighted avg. shares (diluted)39.96M33.93M24.15M19.29M
Balance sheet
Cash & equivalents$80.56M$33.10M$19.34M$18.26M
Receivables$716,095$258,074$153,749—
Current assets$85.10M$34.44M$19.80M$18.59M
PP&E, net$834,429$357,893$409,587$443,464
Total assets$86.15M$34.94M$20.27M$19.12M
Current liabilities$5.63M$3.10M$19.37M$3.06M
Total liabilities$5.70M$3.10M$19.37M$11.91M
Shareholders' equity$82.04M$33.40M$2.22M$7.79M
Shares outstanding51.94M35.64M27.28M21.59M
Cash flow statement
Operating cash flow-$28.55M-$29.99M-$20.75M-$14.40M
Investing cash flow-$588,947-$75,159-$73,377$9.83M
Financing cash flow$76.06M$45.78M$21.08M$10.80M
Depreciation & amortization$237,717$171,719$155,527$147,894
Stock-based compensation$8.76M$3.22M$1.41M$1.43M

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.